Amgen Is Maintained at Buy by Argus Research

Amgen Is Maintained at Buy by Argus Research

Dow JonesJun 28 01:57

Argus Research Maintains Buy on Amgen, Raises Price Target to $340

Argus Research analyst David Toung maintains Amgen (NASDAQ:AMGN) with a Buy and raises the price target from $300 to $340.

BenzingaJun 28 01:47

Amgen Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 8.83% Argus Research $300 → $340 Maintains Buy 06/14/2024 6.27% RBC Capital $328 → $332 Maintai

BenzingaJun 28 01:46

Argus Research Maintains Amgen(AMGN.US) With Buy Rating, Raises Target Price to $340

Argus Research analyst Jasper Hellweg maintains $Amgen(AMGN.US)$ with a buy rating, and adjusts the target price from $310 to $340.According to TipRanks data, the analyst has a success rate of 60.5% a

Futu NewsJun 28 01:32 · Ratings

Novo Nordisk, Eli Lilly Still Top 2 Pharma Stocks: Analyst

Novo Nordisk (NVO) and Eli Lilly (LLY) both made headlines recently with positive drug trial results for their respective GLP-1 weight-loss drugs, as well as their approval in China.

Yahoo FinanceJun 26 22:48

Novo-Nordisk's "miracle weight-loss drug" has been approved domestically, waiting to explode onto the multi-billion dollar market! How to capture this wave of "weight-loss fever"?

With the relentless competition among pharmaceutical research and development companies, the indications for GLP-1 are expected to continuously expand, and institutions are also constantly revising their expectations for the market size of weight-loss drugs.

Futu NewsJun 26 19:59